Interstitial Pneumonitis during Imatinib Therapy in a Patient with Gastrointestinal Stromal Tumor: A Case Report
نویسندگان
چکیده
Gastrointestinal stromal tumors (GISTs) are rare tumors, with an estimated unadjusted incidence of around 1/100 000/ year [1]. It is a result of mutations in KIT tyrosine kinase and in platelet-derived growth factor receptor α (PDGFRA) [2,3]. These mutations are targeted by Imatinib Mesylate in the metastatic,adjuvant and neoadjuvant setting [4,5]. This drug blocks also the BCR-ABL tyrosine kinase in chronic myeloid leukemia (CML) [6]. Imatinib is generally well tolerated with mild common toxicities such as diarrhea, fatigue, skin rash and edema, however pulmonary complications are uncommon [6] we report a case of Imatinib–induced pulmonary toxicity which was treated successfully.
منابع مشابه
Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
Imatinib mesylate is a targeted therapy that acts by inhibiting tyrosine kinase of the bcr-abl fusion oncoprotein, which is specific to chronic myeloid leukemia (CML), and the c-transmembrane receptor, which is specific to gastrointestinal stromal tumors. Interstitial pneumonitis is a rare adverse event of imatinib therapy. It is clinically difficult to distinguish from infectious pneumonia, wh...
متن کاملResponse to imatinib rechallenge in a patient with a recurrent gastrointestinal stromal tumor after adjuvant therapy: a case report
INTRODUCTION Adjuvant imatinib improves recurrence-free survival of patients following resection of primary KIT-positive gastrointestinal stromal tumors. However, it is unknown whether patients who previously received adjuvant imatinib therapy will respond to imatinib rechallenge as treatment for recurrent disease. Here we present the first report documenting the benefits of imatinib rechalleng...
متن کاملSynchronous Gastrointestinal Stromal Tumor and Axillary Deep Fibromatosis: A Rare Association
Gastrointestinal Stromal Tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract and most commonly affects the stomach, while fibromatosis is a rare locally aggressive fibrous tissue neoplasm. There have been reports of GIST and fibromatosis occurring in same individual and in most of them fibromatosis occurs within the abdomen. In 75% of patients fibromatosis occurs aft...
متن کاملGastric Calcifying Fibrous Tumor Resembling Gastrointestinal Stromal Tumor: A Case Report
Calcifying fibrous tumor (CFT) is a rare mesenchymal tumor, affecting children and young adults with a predilection for the soft tissue and the abdominal cavity. CFT of the tubular gastrointestinal tract is very rare with less than 20 cases of gastric CFTs reported in English literature. This benign hypocellular fibrosclerotic calcifying lesion can resemble other spindle cell tumors particularl...
متن کاملPathological complete response in advanced gastric stromal tumor after imatinib mesylate therapy: a case report
INTRODUCTION Gastrointestinal stromal tumors are a rare neoplasm exhibiting, in most cases, mutations of c-kit. Imatinib mesylate is the standard treatment for patients who have advanced gastrointestinal stromal tumors. Although the response rate in patients treated with imatinib mesylate in prospective clinical studies is above 50%, a complete response is very rare. We report the case of a pat...
متن کامل